Journal ArticleDOI
The gut microbiome and efficacy of cancer immunotherapy
TLDR
In this paper , the authors reviewed the highly dynamic and complex microbiome-immune system interface, its bidirectional relationship with cancer immunotherapies, and explored the future possibilities and risks in manipulating the gut microbiome.About:
This article is published in Pharmacology & Therapeutics.The article was published on 2022-03-01. It has received 15 citations till now. The article focuses on the topics: Immunotherapy & Immune system.read more
Citations
More filters
Journal ArticleDOI
Immune checkpoint inhibitor-based therapy for advanced clear cell renal cell carcinoma: A narrative review.
TL;DR: A comprehensive overview of ICI-based therapeutic strategies in advanced clear cell renal cell carcinoma (ccRCC) including their mechanisms of action and the latest clinical evidence is provided in this paper .
Journal ArticleDOI
Dual contribution of the gut microbiome to immunotherapy efficacy and toxicity: supportive care implications and recommendations
Hannah R. Wardill,Raymond Javan Chan,Alexandre Chan,Dorothy M. K. Keefe,Samuel P Costello,Nicolas H. Hart +5 more
TL;DR: In this article , the authors outline strategies at the discovery, translational, and clinical research phases to ensure the impact of augmenting immunotherapy efficacy is approached in a manner that considers adverse implications.
Journal ArticleDOI
The negative effect of antibiotics on RCC patients with immunotherapy: A systematic review and meta-analysis
Zhiqiang Luo,Siyuan Hao,Yuxuan Li,Lei Chen,Xueya Zhou,Emine Gulsen Gunes,Shiyu Liu,Jian Chen +7 more
TL;DR: In this article , a systematic review aimed to assess the impact of ATB on patient survival and tumor response in renal cell carcinoma (RCC) with immunotherapy, which can be regulated by antibiotics (ATB).
Journal ArticleDOI
An immune-related nomogram model that predicts the overall survival of patients with lung adenocarcinoma
TL;DR: In this paper , the authors constructed 6 immune subtypes and compared the difference of progression and overall (OS) time between these immune sub-types and evaluated the relationship with prognosis and introduced lasso-cox method to constructe an immune-related prognosis model.
Journal ArticleDOI
The latest developments in biomarkers predicting response to immunotherapy.
TL;DR: Biomarkers predicting response to immune checkpoint inhibitors can facilitate the selection of patients who benefit from immunotherapy, avoiding rapid disease progression in nonresponders and needless toxicity.
References
More filters
Journal ArticleDOI
Pathogen Recognition and Innate Immunity
TL;DR: New insights into innate immunity are changing the way the way the authors think about pathogenesis and the treatment of infectious diseases, allergy, and autoimmunity.
Journal ArticleDOI
Nivolumab versus docetaxel in advanced squamous-cell non-small-cell lung cancer
Julie R. Brahmer,Karen L. Reckamp,Paul Baas,Lucio Crinò,Wilfried Eberhardt,Elena Poddubskaya,Scott J. Antonia,Adam Pluzanski,Everett E. Vokes,Esther Holgado,David M. Waterhouse,Neal Ready,Justin F. Gainor,Osvaldo Arén Frontera,Libor Havel,Martin Steins,Marina Chiara Garassino,Joachim G.J.V. Aerts,Manuel Domine,Luis Paz-Ares,Martin Reck,Christine Baudelet,Christopher T. Harbison,Brian Lestini,David R. Spigel +24 more
TL;DR: Among patients with advanced, previously treated squamous-cell NSCLC, overall survival, response rate, and progression-free survival were significantly better with nivolumab than with docetaxel, regardless of PD-L1 expression level.
Journal ArticleDOI
Pembrolizumab versus Ipilimumab in Advanced Melanoma
Caroline Robert,Caroline Robert,Caroline Robert,Jacob Schachter,Georgina V. Long,Ana Arance,Jean-Jacques Grob,Laurent Mortier,Laurent Mortier,Adil Daud,Matteo S. Carlino,Catriona M. McNeil,Michal Lotem,James Larkin,Paul Lorigan,Bart Neyns,Christian U. Blank,Omid Hamid,Christine Mateus,Christine Mateus,Ronnie Shapira-Frommer,Ronnie Shapira-Frommer,Michele Kosh,Honghong Zhou,Nageatte Ibrahim,Scot Ebbinghaus,Antoni Ribas +26 more
TL;DR: The anti-PD-1 antibody pembrolizumab prolonged progression-free survival and overall survival and had less high-grade toxicity than did ipilimumab in patients with advanced melanoma.
Journal ArticleDOI
Wnt/β-catenin signaling and disease.
Hans Clevers,Roel Nusse +1 more
TL;DR: An update of the core Wnt/β-catenin signaling pathway is provided, how its various components contribute to disease, and outstanding questions to be addressed in the future are discussed.
Journal ArticleDOI
Induction of Intestinal Th17 Cells by Segmented Filamentous Bacteria
Ivaylo I. Ivanov,Koji Atarashi,Nicolas Manel,Eoin L. Brodie,Tatsuichiro Shima,Ulas Karaoz,Dongguang Wei,Katherine C. Goldfarb,Clark A. Santee,Susan V. Lynch,Takeshi Tanoue,Akemi Imaoka,Kikuji Itoh,Kiyoshi Takeda,Yoshinori Umesaki,Kenya Honda,Dan R. Littman +16 more
TL;DR: The authors showed that colonisation of mice with a segmented filamentous bacterium (SFB) is sufficient to induce the appearance of CD4+ T helper cells that produce IL-17 and IL-22 (Th17 cells) in the lamina propria.
Related Papers (5)
Development of Personalized Combination Cancer Immunotherapy Based on the Patients’ Immune Status
Yutaka Kawakami,Li Qian,Naoshi Kawamura,Junichiro Miyazaki,Haruna Nagumo,Kinya Tsubota,Tomonari Kinoshita,Kenta Nakamua,Gaku Ohmura,Ryosuke Satomi,Juri Sugiyama,Hiroshi Nishio,Taeko Hayakawa,Boryana Popivanova,Sunthamala Nuchsupha,Tracy Hsin-ju Liu,Hajime Kamijuku,Chie Kudo-Saito,Nobuo Tsukamoto,Toshiharu Sakurai,Tomonobu Fujita,Tomonori Yaguchi +21 more